Homologous Recombination Deficiency in Chinese Ovarian Cancer Patients
NCT05044091
·
clinicaltrials.gov ↗
UNKNOWN
Status
100
Enrollment
OTHER
Sponsor class
Conditions
Ovarian Cancer
HRD
PARP Inhibitor
Interventions
DRUG:
PARP inhibitor
Sponsor
Xiaoxiang Chen